Viral Infections Market Size, Share, Growth and Treatment

Summary

Viruses are infectious particles comprising a nucleic acid core – consisting of either DNA or RNA – and a protein coat known as a capsid. Infections attributable to viral pathogens are transmitted, directly or indirectly, from one person to another or from animal to human. Viruses replicate by exploiting the resources of their host cells, usually to the detriment of the host. As viral pathogens are exceptionally diverse, the morbidity associated with viral infections varies significantly depending on the virus in question. This report covers all viral infections, although particular focus is given to four key indications within this disease cluster: Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV) and influenza. The global viral infections market was valued at $74.0 billion in 2014, and is projected to grow at a considerable Compound Annual Growth Rate (CAGR) of 6.8%, reaching $117.6 billion in 2021. Key drivers of this growth will be the expanding treatment population and uptake of recently approved highly priced antiviral agents, as well as promising late-stage candidates that are expected to be priced highly.

Browse Detail Report With TOC @ http://www.hexareports.com/report/global-viral-infections-market-to-2021/details

Scope

The viral infections market is large and growing rapidly

- How do epidemiology trends differ among the key indications?

- What therapeutic options exist for preventing and treating viral infections?

- Which products and companies dominate the market?

The pipeline is innovative and diverse

- What is the proportion of early- to late-stage pipeline products?

- Which molecular targets are most prominent within the pipeline?

- How do the key indications differ in terms of molecule type?

Considerable market growth is anticipated throughout 2021

- Which products will contribute to this growth most significantly?

- Will the current market leaders retain their dominance over...